ES2160601T3 - Vacunas de conjugado de polisacaridos de estreptococos del grupo b tipo ii y tipo v-proteina. - Google Patents

Vacunas de conjugado de polisacaridos de estreptococos del grupo b tipo ii y tipo v-proteina.

Info

Publication number
ES2160601T3
ES2160601T3 ES93922357T ES93922357T ES2160601T3 ES 2160601 T3 ES2160601 T3 ES 2160601T3 ES 93922357 T ES93922357 T ES 93922357T ES 93922357 T ES93922357 T ES 93922357T ES 2160601 T3 ES2160601 T3 ES 2160601T3
Authority
ES
Spain
Prior art keywords
type
group
protein
streptococes
streptococo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93922357T
Other languages
English (en)
Inventor
Harold J Jennings
Dennis L Kasper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council Canada
The Brigham and Women's Hospital Inc
Original Assignee
National Research Council Canada
The Brigham and Women's Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26823688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2160601(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by National Research Council Canada, The Brigham and Women's Hospital Inc filed Critical National Research Council Canada
Application granted granted Critical
Publication of ES2160601T3 publication Critical patent/ES2160601T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813—Carrier is a saccharide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

LA INVENCION SE REFIERE A MOLECULAS CONJUGADAS ANTIGENICAS QUE COMPRENDEN EL POLISACARIDO CAPSULAR DE LOS ESTREPTOCOCOS GRUPO B TIPO II LOS CUALES ESTAN ENLAZADOS DE MODO COVALENTE CON LA PROTEINA. ESTA INVENCION SE REFIERE ADEMAS A MOLECULAS CONJUGADAS ANTIGENICAS QUE COMPRENDEN EL POLISACARIDO CAPSULAR DE LOS ESTREPTOCOCOS GRUPO B TIPO V LOS CUALES ESTAN ENLAZADOS DE MODO COVALENTE CON LA PROTEINA. ESTA INVENCION TAMBIEN SE REFIERE A VACUNAS Y METODOS DE INMUNIZACION DE MAMIFEROS, INCLUYENDO A LAS PERSONAS CONTRA LA INFECCION POR ESTREPTOCOCOS GRUPO B TIPO II (GBS II) Y/O ESTREPTOCOCOS GRUPO B TIPO V (GBS V). TAMBIEN SON REIVINDICADAS LAS VACUNAS MULTIVALENTES LAS CUALES COMPRENDEN LAS MOLECULAS CONJUGADAS DE ESTA INVENCION Y LOS ANTIGENOS PARA OTRAS BACTERIAS PATOGENICAS.
ES93922357T 1992-09-24 1993-09-24 Vacunas de conjugado de polisacaridos de estreptococos del grupo b tipo ii y tipo v-proteina. Expired - Lifetime ES2160601T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94997092A 1992-09-24 1992-09-24
US12555693A 1993-09-23 1993-09-23

Publications (1)

Publication Number Publication Date
ES2160601T3 true ES2160601T3 (es) 2001-11-16

Family

ID=26823688

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93922357T Expired - Lifetime ES2160601T3 (es) 1992-09-24 1993-09-24 Vacunas de conjugado de polisacaridos de estreptococos del grupo b tipo ii y tipo v-proteina.

Country Status (16)

Country Link
US (2) US5795580A (es)
EP (1) EP0667787B1 (es)
JP (3) JP4163251B2 (es)
KR (1) KR100293017B1 (es)
AT (1) ATE203167T1 (es)
AU (1) AU690525B2 (es)
CA (1) CA2145397C (es)
DE (1) DE69330464T2 (es)
DK (1) DK0667787T3 (es)
ES (1) ES2160601T3 (es)
FI (1) FI110993B (es)
GR (1) GR3036928T3 (es)
IL (1) IL107103A (es)
NO (2) NO319569B1 (es)
NZ (2) NZ299249A (es)
PT (1) PT667787E (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69719677T2 (de) * 1996-11-18 2003-09-18 Japan Storage Battery Co. Ltd., Kyoto Positivelektrode für Lithiumbatterie und Lithiumbatterie
CA2320470A1 (en) * 1998-02-05 1999-08-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
AU2001281168A1 (en) 2000-08-08 2002-02-18 St. Jude Children's Research Hospital Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
SV2003000753A (es) * 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
US20030185858A1 (en) * 2001-08-15 2003-10-02 Birkett Ashley J. Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
WO2003015815A1 (en) * 2001-08-21 2003-02-27 The Brigham And Women's Hospital, Inc. Improved conjugate vaccines
US20040096461A1 (en) * 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
AU2004227852B2 (en) 2003-03-31 2010-01-14 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
ES2317043T3 (es) * 2003-06-23 2009-04-16 Baxter International Inc. Proteinas portadoras para vacunas.
MX2007005202A (es) * 2004-11-01 2007-07-09 Brigham & Womens Hospital Polisacaridos de estreptococo modificados y usos de los mismos.
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
WO2007092451A2 (en) * 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
GB201101665D0 (en) * 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
CN104582718B (zh) 2012-10-03 2017-10-24 诺华股份有限公司 免疫原性组合物
KR102143534B1 (ko) * 2015-05-04 2020-08-12 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
CN108135167B (zh) 2015-08-19 2021-07-09 哈佛学院院长及董事 脂化psa组合物和方法
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
CA3139257A1 (en) * 2019-05-10 2020-11-19 Glaxosmithkline Biologicals Sa Conjugate production

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324887A (en) * 1978-08-16 1982-04-13 President And Fellows Of Harvard College Type II group B Streptococci polysaccharide
US4207414A (en) * 1978-08-16 1980-06-10 President And Fellows Of Harvard College Polysaccharide antigens
IE51174B1 (en) * 1980-04-14 1986-10-29 Merck & Co Inc Group b streptococcal capsular polysaccharides
US4438261A (en) * 1980-05-19 1984-03-20 Riker Laboratories, Inc. Anticoagulant substance
US4367221A (en) * 1980-06-09 1983-01-04 President And Fellows Of Harvard College Immunization against Group B streptococci
US4367223A (en) * 1980-06-09 1983-01-04 President And Fellows Of Harvard College Vaccine against Group B streptococci
US4367222A (en) * 1980-06-09 1983-01-04 President And Fellows Of Harvard College Immune globulin specific to Group B streptococci
US4356263A (en) * 1980-06-09 1982-10-26 President And Fellows Of Harvard College Method of making a polysaccharide vaccine
US4284537A (en) * 1980-07-03 1981-08-18 The United States Of America As Represented By The Department Of Health And Human Services Conjugate of streptococcal M protein peptide vaccine
US4425330A (en) * 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4757134A (en) * 1982-12-02 1988-07-12 The Rockefeller University IgA binding protein
EP0175261B1 (en) * 1984-09-12 1991-12-11 Chiron Corporation Hybrid particle immunogens
FR2581877B1 (fr) * 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
US5302386A (en) * 1986-04-16 1994-04-12 Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines and methods of manufacture
JP2754000B2 (ja) * 1986-04-16 1998-05-20 ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイテッド 細菌抗原、抗体、ワクチン及びその製造方法
NZ225372A (en) * 1987-07-17 1991-04-26 Xoma Corp Immunotoxin composition comprising purified ricin-a-chain species
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp Conjugate vaccine formed from a polysaccharide and a c protein of b-streptococcus
RO111416B1 (ro) * 1989-12-14 1996-10-31 Ca Nat Research Council Polizaharide modificate de neisseria meningitidis si e coli, combinatii antigenice si metoda de imunizare
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.

Also Published As

Publication number Publication date
DE69330464T2 (de) 2001-11-08
JPH08501563A (ja) 1996-02-20
NZ299249A (en) 2000-08-25
KR950703361A (ko) 1995-09-20
FI951412L (fi) 1995-05-24
CA2145397C (en) 2007-10-30
FI951412A0 (fi) 1995-03-24
NZ248766A (en) 1996-11-26
FI110993B (fi) 2003-05-15
EP0667787A1 (en) 1995-08-23
EP0667787B1 (en) 2001-07-18
NO951109L (no) 1995-05-22
JP2005306884A (ja) 2005-11-04
IL107103A0 (en) 1994-08-26
AU690525B2 (en) 1998-04-30
JP4308174B2 (ja) 2009-08-05
CA2145397A1 (en) 1994-03-31
KR100293017B1 (ko) 2001-09-17
JP4163251B2 (ja) 2008-10-08
DK0667787T3 (da) 2001-10-29
IL107103A (en) 2001-03-19
US5795580A (en) 1998-08-18
NO951152D0 (no) 1995-03-24
NO319569B1 (no) 2005-08-29
JP2009132727A (ja) 2009-06-18
PT667787E (pt) 2001-10-31
US5993825A (en) 1999-11-30
DE69330464D1 (en) 2001-08-23
AU5137893A (en) 1994-04-12
NO951109D0 (no) 1995-03-23
ATE203167T1 (de) 2001-08-15
GR3036928T3 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
ES2152421T3 (es) Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas.
BR9106748A (pt) Vacina de hyopneumomiae micoplasma inativado e metodo de seu uso
ES2121820T3 (es) Vacuna de conjugados de polisacaridos de neumococos.
ATE127345T1 (de) Stressproteine und verwendungen dafür.
ES2196024T3 (es) Vacunas conjugadas de gangliosido-klh con qs-21.
ES2164251T3 (es) Vacuna que comprende un conjugado antigeno polisacarido-proteina transportadora y proteina transportadora libre.
ES2152483T3 (es) Aplicacion terapeutica en anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de celulas b.
NO20015073L (no) Vaksiner
ES2070266T3 (es) Vacuna contra la infeccion por escherichia coli.
ES2180758T3 (es) Vacunas de pertussis acelulares y metodos de preparacion de las mismas.
CY1108147T1 (el) Εμβολιο κατα των σεξουαλικως μεταδιδομενων νοσων
CA2145397A1 (en) Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
ES2137310T3 (es) Vacuna contra una infeccion por streptococcus suis.
NL300185I1 (nl) Acellulair vaccin.
ES2100893T3 (es) Procedimiento de preparacion de una vacuna o de un agente toxico.
MX9301736A (es) Vacuna de bacterina-toxoide de pasteurella haemolytica tipo a-1.
ES2102836T3 (es) El empleo de vacunas antihelminticas en el control de la enfermedad parasitaria asociada con la perdida de la inmunidad natural.
ES2055164T3 (es) Preparaciones efectivas contra infecciones por pseudomonas aeruginosa asi como preparaciones que contienen inmunoglobulina-g, efectivas contra la bacteria pseudomonas aeruginosa.
CO5241277A1 (es) Vacuna
PT1313500E (pt) Associacoes de dalfopristina/quinupristina com o cefpirome

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 667787

Country of ref document: ES